Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012701 | 0.83 | OPRM1 (0.44) | CYP11B2CYP11B1CYP19A1ADRA2BCHRNB4 | |
| Hydrochloric Acid SCHEMBL19991666 | 0.81 | OPRM1 (0.43) | CYP11B2CYP11B1CYP19A1ADRA2BCHRNB4 | |
| SCHEMBL20009027 | 0.78 | CYP11B2 (0.35) | CYP11B2CYP11B1CYP19A1ADRA2BCHRNB4 | |
| SCHEMBL19991715 | 0.70 | GPR119 (0.44) | — | |
| SCHEMBL7146555 | 0.68 | CHRNB2 (0.46) | CYP11B2CHRNB4CHRNA3 | |
| SCHEMBL7565522 | 0.68 | CHRNB2 (0.46) | CYP11B2CHRNB4CHRNA3 | |
| SCHEMBL4825581 | 0.68 | CYP11B2 (0.38) | CYP11B2CHRNB4CHRNA3EPAS1RIPK1 | |
| SCHEMBL5094697 | 0.67 | CYP11B2 (0.37) | CYP11B2CHRNB4CHRNA3EPAS1RIPK1 | |
| SCHEMBL23515071 | 0.66 | KDM4E (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL4820560 | 0.66 | PIM1 (0.46) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | CYP11B2 1636/4885CYP11B1 1203/4885CYP19A1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.